A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) * Address for reprints: Southwest Oncology Group (SWOG-9407), Operations Office, 14980 Omnicron Dr., San Antonio, TX 78245-3217
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.contributor.author | Fisher, Emily I. | en_US |
dc.contributor.author | Eisenberger, Mario A. | en_US |
dc.contributor.author | Mills, Glenn M. | en_US |
dc.contributor.author | Goodwin, J. Wendall | en_US |
dc.contributor.author | Jones, Jeffrey A. | en_US |
dc.contributor.author | Dakhil, Shaker R. | en_US |
dc.contributor.author | Crawford, E. David | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.date.accessioned | 2006-04-19T13:48:59Z | |
dc.date.available | 2006-04-19T13:48:59Z | |
dc.date.issued | 2001-03-01 | en_US |
dc.identifier.citation | Pienta, Kenneth J.; Fisher, Emily I.; Eisenberger, Mario A.; Mills, Glenn M.; Goodwin, J. Wendall; Jones, Jeffrey A.; Dakhil, Shaker R.; Crawford, E. David; Hussain, Maha H.A. (2001)."A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) * Address for reprints: Southwest Oncology Group (SWOG-9407), Operations Office, 14980 Omnicron Dr., San Antonio, TX 78245-3217 ." The Prostate 46(4): 257-261. <http://hdl.handle.net/2027.42/34757> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34757 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11241547&dopt=citation | en_US |
dc.description.abstract | BACKGROUND The combination of oral estramustine and oral etoposide has generated response rates of 40–50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS Fifty-five patients were accrued over a period of 4 months between 1 March 1996 and 1 July 1996. Two patients were not analyzable and two patients were ineligible. They were given an oral regimen consisting of estramustine 15 mg/kg/day (capped at 1120 mg per day) and etoposide 50 mg/M 2 /day, days 1–21 every 28 days. Patients received a median of two cycles of therapy. RESULTS Toxicities included 11 patients (20%) with grades 3 or 4 granulocytopenia, 5 patients (10%) with grades 3 or 4 edema, and 3 patients (6%) with a thrombotic event. There were two treatment-related deaths, one as a result of anemia and the other as a result of a myocardial infarction. Of the 32 men who received at least 2 cycles of therapy, 7 men (22%) demonstrated a partial response to this regimen as measured by prostate-specific antigen (PSA) criteria of a 50% decline from pretreatment values. CONCLUSIONS This trial demonstrates the toxicity of estramustine delivered in high dose. It also illustrates the difficulty of conducting phase II trials in prostate cancer in the cooperative group setting where the experience and comfort level of oncologists with new agents is less than that of the physicians at the institution where the therapy was developed. As the activity of this regimen with low-dose estramustine is defined, further multi-institutional studies may be warranted. Prostate 46:257–261, 2001. © 2001 Wiley-Liss, Inc. | en_US |
dc.format.extent | 75900 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) * Address for reprints: Southwest Oncology Group (SWOG-9407), Operations Office, 14980 Omnicron Dr., San Antonio, TX 78245-3217 | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, Michigan ; 1500 E. Medical Center Drive- 7303 CCGC, Ann Arbor, MI 48109-0946. | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Johns Hopkins Oncology Center, Baltimore, Maryland | en_US |
dc.contributor.affiliationother | Louisiana State University-Shreveport, Louisiana | en_US |
dc.contributor.affiliationother | Ozarks Regional CCOP, Springfield, Missouri | en_US |
dc.contributor.affiliationother | Texas Tech University, Lubbock, Texas | en_US |
dc.contributor.affiliationother | Wichita CCOP, Wichita, Kausas | en_US |
dc.contributor.affiliationother | University of Colorado, Denver, Colorado | en_US |
dc.contributor.affiliationother | Wayne State University/Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan | en_US |
dc.identifier.pmid | 11241547 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34757/1/1031_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/1097-0045(20010301)46:4<257::AID-PROS1031>3.0.CO;2-4 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.